NEW YORK, June 02, 2022 (GLOBE NEWSWIRE) -- Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest comments and insights from CEO’s of: Tonix Pharmaceuticals (NASDAQ: TNXP), Nova Mentis Life Sciences (OTC: NMLSF) (CSE: NOVA), PDS Biotechnology (NASDAQ: PDSB) and AI/ML Innovations (OTC: AIMLF) (CSE: AIML). As the global pharma market surpasses $1.3 trillion dollars (Statista), emerging technologies and healthcare research innovations are unleashing new exponential growth opportunities. As the biotech sector rebounds from cyclical lows, institutional investors are increasingly eyeing early-stage biotech stocks for upside potential delivering alpha. Wall Street Reporter highlights the latest comments from industry thought leaders shaping our world today, and in the decades ahead:
PDS Biotechnology (NASDAQ: PDSB) CEO Frank Bedu-Addo: “FDA Fast Track Underscores Potential of Versamune Platform”
PDS Biotechnology Corporation (NASDAQ: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of molecularly targeted cancer immunotherapies and infectious disease vaccines based on the Company’s proprietary Versamune® and Infectimune™ T cell activating technologies, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to PDS0101 in combination with Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab). PDS0101 in combination with KEYTRUDA® is being studied in the VERSATILE-002 Phase 2, open-label, multicenter trial for the treatment of recurrent or metastatic HPV16-positive head and neck cancer in collaboration with Merck. PDSB CEO Frank Bedu-Addo, Ph.D, commented: “We are thrilled that the FDA has granted Fast Track designation for PDS0101 in combination with KEYTRUDA®. The HPV-associated head and neck cancer prevalence continues to rise, leaving this affected group with limited treatment options to date. Receiving this designation underscores the potential of the Versamune® platform and the need for a new therapy that may improve outcomes for those with this devastating disease.”
PDS Biotechnology (NASDAQ: PDSB) NEWS: https://www.wallstreetreporter.com/2022/06/02/pds-biotechnology-nasdaq-pdsb-granted-fda-fast-track-designation-for-lead-candidate-pds0101/
Nova Mentis Life Sciences (OTC: NMLSF) (CSE: NOVA) CMO Marvin Hausman, M.D.: “Nova’s Psilocybin-based Therapeutics Showing Vast Promise for Autism and Other Neuroinflammatory Disorders”
Nova Mentis Life Sciences (OTC: NMLSF) (CSE: NOVA) a featured presenter at Wall Street Reporter’s NEXT SUPER STOCK investor conference is advancing psilocybin-based novel therapeutics, targeting autism spectrum disorders, an unmet medical need with multi-billion dollar market potential. NMLSF Chief Medical Officer Dr. Marvin Hausman, M.D., has a decades-long track record of success advancing new drugs through the FDA regulatory pathways, into commercialization, generating billions of dollars in revenue. Dr. Hausman is now bringing the “same playbook” to NMLSF for its psilocybin-based therapeutics targeting Fragile X, then potential expansion to treat other neuroinflammatory disorders, including alzheimers, and parkinsons. NMLSF plans to submit a clinical trial application to Health Canada for a Phase 2A study evaluating its psilocybin microdose therapy for Fragile X Syndrome, in the coming weeks.
NMLSF is a global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders. NMLSF is the first biotech company to achieve FDA “Orphan Drug Designation” in both the United States and European Union for the use of psilocybin in the treatment of FXS. In his interview with Wall Street Reporter, Dr. Hausman explains his strategy for advancing NMLSF’s drug pipeline through commercialization, as he has successfully accomplished with other novel drugs during his decades-long career.
Watch NEXT SUPER STOCK Nova Mentis (OTC: NMLSF) (CSE: NOVA) Video: https://www.wallstreetreporter.com/2022/03/25/next-super-stock-nova-mentis-life-sciences-otc-nmlsf-billions-opportunity-w-autism-psilocybin/
"The recently completed preclinical study of repeat low doses of our psilocybin drug - every other day for 2 weeks, showed clinical responses that greatly exceeded our expectations. We significantly modulated behavioural and cognitive defects, such as recognition memory, in FXS." NMLSF plans to submit a clinical trial application to Health Canada in the coming weeks for a Phase 2A study evaluating psilocybin microdose therapy for FXS. "Autism spectrum disorder ("ASD") and especially FXS, the largest genetic cause of ASD, continue to have unmet medical needs. Scientists at NOVA, over the past two years, have laid the groundwork for development of potential novel psilocybin-based microdose treatment of ASD," said NMLSF Chief Medical Officer, Dr. Marvin S. Hausman, MD.
Watch NEXT SUPER STOCK Nova Mentis (OTC: NMLSF) (CSE: NOVA) Video: https://www.wallstreetreporter.com/2022/03/25/next-super-stock-nova-mentis-life-sciences-otc-nmlsf-billions-opportunity-w-autism-psilocybin/
AI/ML Innovations (OTC: AIMLF) (CSE: AIML) Chairman, Tim Daniels: “AI/ML Holds Key Patents for Multi-Billion Dollar Healthcare Wearables Market”
AI/ML Innovations (OTC: AIMLF), a featured presenter at Wall Street Reporter's "Next Super Stock" investor conference series, recently updated investors on growth initiatives at AIMLF’s portfolio of digital health businesses including HealthGauge, a wearable personal health monitoring & management system, using Artificial Intelligence and Machine Learning, and Tech2Heal a European mental health app innovator.
Of significant interest for investors is AIMLF’s landmark patent position for wearable health monitors - which could position AIMLF to collect licensing fees and royalties on the $13.8 Billion global Smart Wearable Healthcare Devices (projected to reach $37.4 Billion by 2028. Source: Verified Market Research.) AIMLF is now starting to license its technologies to health wearables companies, and collecting royalties. With typical royalties of 2% of gross sales, AIMLF could potentially generate significant recurring revenues from companies infringing on its broad patent position in the nearly $14 billion health wearables market.
Watch AI/ML Innovations (OTC: AIMLF) (CSE: AIML) NEXT SUPER STOCK Video:
https://www.wallstreetreporter.com/2022/05/31/next-super-stock-ai-ml-billion-dollar-patent/
AIMLF’s Health Gauge subsidiary, has recently been granted a patent by the United States Patent and Trademark Office (US Patent No. 11183303), titled "Wearable Health Monitors and Methods of Monitoring Health". The Patent covers Cardiovascular monitoring, Predictive health analysis, Behavioral analysis and 64 other claims, including use of multiple configurations of wearable health monitors, in conjunction with methods of analyzing bio-signals and monitoring health metrics (via Health Gauge's AI-driven software) for the purpose of assisting the user in achieving their personal health and wellness objectives.
AIMLF is reporting advancing growth at its portfolio company Tech2Heal, a European mental health app innovator. Tech2Heal is positioned for explosive revenue growth as European healthcare mandates now provide about 2,500 Euro per patient annually for mental wellness. Tech2Heal has just signed with a French multinational manufacturer, to provide mental wellness support to their 170,000 employees globally, and additional Enterprise contracts are in the pipeline. Tim Daniels also updated investors on AIML’s growing pipeline of M&A opportunities in the HealthTech space, which could have a positive impact on maximizing shareholder value in coming months.
Watch AI/ML Innovations (OTC: AIMLF) (CSE: AIML) NEXT SUPER STOCK Video:
https://www.wallstreetreporter.com/2022/05/31/next-super-stock-ai-ml-billion-dollar-patent/
Tonix Pharmaceuticals (NASDAQ: TNXP) CEO Seth Lederman, M.D.: “Expanding Pipeline of Vaccines”
Tonix Pharmaceuticals (NASDAQ: TNXP), a clinical-stage biopharmaceutical company, announced the United States Patent and Trademark Office Patent No. 11,345,896 to the Company on May 31, 2022 entitled "Synthetic Chimeric Poxviruses," includes claims covering synthetic horsepox virus, the basis for the Company’s TNX-8011 vaccine in development to protect against monkeypox and smallpox and for the Company’s Recombinant Pox Virus (RPV) platform to protect against other pathogens, including SARS-CoV-2. This patent is expected to provide Tonix with U.S. market exclusivity until 2037, excluding any possible patent term extensions or patent term adjustments.
TNXP CEO Seth Lederman, M.D., commented: “This patent is an important milestone in protecting our expanding pipeline of vaccines that address known and potentially novel pathogens.TNX-801 is a horsepox-based live virus vaccine currently in development to protect against monkeypox and smallpox. TNX-18401 and TNX-18501 are designed to express the spike proteins from the SARS-CoV-2 omicron and BA.2 variants, respectively. Horsepox was one of the first few viruses ever generated by synthetic biology and remains among the largest.”
Tonix Pharmaceuticals (NASDAQ: TNXP) NEWS: https://www.wallstreetreporter.com/2022/06/02/tonix-pharmaceuticals-nasdaq-tnxp-announces-issuance-of-u-s-patent/
WALL STREET REPORTER
Wall Street Reporter (Est. 1843) is the leading financial news provider, focused on giving investors direct access to CEO's of promising, publicly-traded companies, and market experts. www.WallStreetReporter.com. Nothing in this news summary shall be construed as investment advice. Quotes/content may be edited for brevity and context. Full disclaimer, and relevant SEC 17B disclosures here: https://tinyurl.com/2x4eznd5
About Wall Street Reporter’s Next Super Stock conference:
Wall Street Reporter's NEXT SUPER STOCK Live! conference is dedicated to featuring select companies that have near-term catalysts in place which can drive transformational growth (and stock appreciation) in the months ahead. Click here to join next livestream event: https://www.wallstreetreporter.com/next-superstock-online-investor-conference/
CONTACT:
WALL STREET REPORTER
(212) 871-2057 ext 7
